Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aimed bio

Request full access

Innovative brain therapeutics leveraging BBB crossing technologies and precision medicine for neurodegenerative diseases

Seoul, South KoreaFounded 2018Biotech & Life Sciences

About Aimed bio

AIMEDBIO is a pioneering company in the field of brain therapeutics, focusing on the development of treatments for neurodegenerative diseases. The company leverages its proprietary Blood-Brain Barrier (BBB) crossing technologies and precision medicine platform to identify and target brain-specific conditions. AIMEDBIO operates in the healthcare and biotechnology market, primarily serving patients suffering from brain diseases such as neuro-oncology and neurology disorders. The business model revolves around extensive research and development (R&D) pipelines, which are aimed at creating efficient and effective brain-specific immune modulators and therapeutics. Revenue is generated through the development and commercialization of these advanced treatments. The company's long-standing expertise in brain research, combined with big data analysis, positions it as a leader in the field of brain disease treatment. AIMEDBIO's commitment to innovation and scientific breakthroughs continues to drive its mission of providing optimal solutions for individual patients.

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
83.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest Aug 2026
Capital deployed
$31M
Preferred round
SERIES B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Dec 2025 $59M — Undisclosed —
LATE VCOther financing Jun 2025 $43M $171M Undisclosed ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Aimed bio website traffic

Latest recorded traffic for Aimed bio is 4.6K monthly website visits, down 34.3% over the last three months. Aimed bio's team grew 6.7% over the past year.

Latest monthly visits4.6K 3-month web change-34.3% 1-year team growth+6.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Aimed bio in the Seoul ecosystem

Live from Dealroom

The Aimed bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Samsung Bioepis
  • Samsung C&T’s Engineering & Construction
  • Samsung BioLogics
  • InterVest
  • DS Asset Management
  • Samsung Life Science Fund
  • Samsung Life Public Welfare Foundation
  • Mint Venture Partners

Other known investors1 additional known investor

  • Samsung Medical Center
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Aimed bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.